|
|
|
|
|
|
Sponsored by: |
Solvay Pharmaceuticals |
Information provided by: | Solvay Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00325260 |
In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy. In addition, safety and efficacy data with Influvac will be assessed in the Chinese population.
Condition | Intervention | Phase |
Healthy |
Biological: Influvac; subunit influenza vaccine |
Phase III |
MedlinePlus related topics: | Flu |
ChemIDplus related topics: | Influenza Vaccines Fluvirin |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac® to the Subunit Influenza Vaccine Agrippal® in Healthy Children, Adults and Elderly in China. |
Ages Eligible for Study: | 3 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | S201.3.121 |
First Received: | May 11, 2006 |
Last Updated: | October 31, 2006 |
ClinicalTrials.gov Identifier: | NCT00325260 |
Health Authority: | China: State Food and Drug Administration |
|
|